PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 13 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

9 April 2026

  1. (diff | hist) 13:25 Talk:Lixisenatide 611 +128 ExenatideEzra (talk | contribs) /* Counter-example framing */ reply
  2. (diff | hist) m 11:58 SELECT trial 5,171 ±0 Chromatokid (talk | contribs) the percentage quoted was placebo-adjusted; label it [rollback]
  3. (diff | hist) 10:50 Talk:Gastric emptying 537 +156 HedgeHedda (talk | contribs) /* Tachyphylaxis wording */ new section
  4. (diff | hist) 10:20 Talk:Syringe dead space 1,307 +218 Ref_Desk_Ron (talk | contribs) /* Is the community measurement tally worth citing at all? */ reply
  5. (diff | hist) 09:50 Talk:Lixisenatide 400 +130 SelectTrialSam (talk | contribs) /* Counter-example framing */ new section
  6. (diff | hist) 09:13 Contraindications of incretin therapy 4,993 ±0 AppendixAlva (talk | contribs) correct the percentage — source reports it per patient-year [rollback]

8 April 2026

  1. (diff | hist) 16:11 Sterility testing 4,776 ±0 AxisLabelAgda (talk | contribs) clarify that area percent is not mass percent [rollback]
  2. (diff | hist) 15:10 Talk:Incretin effect 1,022 +134 Ref_Desk_Ron (talk | contribs) /* Measurement methods: mention the glucagon secretion measurement too? */ reply
  3. (diff | hist) 14:55 Talk:Chain of custody 748 +127 VerifyVesna (talk | contribs) /* Direct supplier-to-laboratory shipment */ reply
  4. (diff | hist) 13:55 Talk:Customs seizure 748 +100 ImportRecordIna (talk | contribs) /* No avoidance methods */ reply
  5. (diff | hist) m b 13:22 GLP-1 receptor agonist 11,264 ±0 CiteBot (talk | contribs) bot: repair redlinked category [rollback]
  6. (diff | hist) 12:33 Talk:Incretin effect 811 +236 AnalyticalAnnie (talk | contribs) /* Measurement methods: mention the glucagon secretion measurement too? */ new section
  7. (diff | hist) 11:25 Talk:Chain of custody 537 +185 BlindSampleBrid (talk | contribs) /* Direct supplier-to-laboratory shipment */ new section
  8. (diff | hist) 10:50 SinoPep 18,360 +220 ChainCustodyChad (talk | contribs) label the reception tally as weak, self-selected evidence at this point of use [rollback]
  9. (diff | hist) 10:20 Talk:Customs seizure 537 +149 NPOV_Nadia (talk | contribs) /* No avoidance methods */ new section
  10. (diff | hist) m 09:15 Xi'an Mokemei Biotechnology 15,421 ±0 LipidLedgerLou (talk | contribs) expand §Independent testing record [rollback]

7 April 2026

  1. (diff | hist) 19:16 Janoshik Analytical 5,235 ±0 TallySheetTad (talk | contribs) rm the ranking language; this wiki publishes no ranking [rollback]
  2. (diff | hist) m 17:33 GL Biochem (Shanghai) 16,491 ±0 PurityClaimPia (talk | contribs) add the how-to-request-a-batch-record sentence to §Ordering and availability [rollback]
  3. (diff | hist) m b 14:53 Prescribing information 4,506 ±0 ArchiveBot (talk | contribs) bot: flag bare reference [rollback]
  4. (diff | hist) 13:55 Talk:Fmoc chemistry 748 +113 ResinRhoswen (talk | contribs) /* Deprotection monitoring */ reply
  5. (diff | hist) 13:48 Talk:Albumin binding half-life extension 611 +226 MolarMassMaeve (talk | contribs) /* Bound fraction figure */ reply
  6. (diff | hist) 10:22 Talk:Albumin binding half-life extension 400 +160 HalfLifeHavel (talk | contribs) /* Bound fraction figure */ new section
  7. (diff | hist) 10:20 Talk:Fmoc chemistry 537 +118 SPPS_Sorrel (talk | contribs) /* Deprotection monitoring */ new section
  8. (diff | hist) 08:52 Talk:Syringe dead space 1,096 +274 VerifyFirstVida (talk | contribs) /* Is the community measurement tally worth citing at all? */ reply
  9. (diff | hist) m 08:40 Global access disparity 4,391 ±0 TierTwoTansy (talk | contribs) give the cost per unit of effect rather than only the cost [rollback]
  10. (diff | hist) m 05:08 Growth hormone secretagogue 4,613 ±0 ReportReaderRilla (talk | contribs) add the parent protein and the residue range the fragment spans [rollback]
  11. (diff | hist) m b 04:12 Methionine oxidation 5,001 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  12. (diff | hist) 03:15 Residual solvent 5,085 ±0 DiluentDiya (talk | contribs) clarify that area percent is not mass percent [rollback]

6 April 2026

  1. (diff | hist) m 20:06 Cold chain 27,220 ±0 PrepHPLC_Pia (talk | contribs) expand §Mean kinetic temperature [rollback]
  2. (diff | hist) 15:44 Talk:Syringe dead space 885 +329 DeadSpaceDot (talk | contribs) /* Is the community measurement tally worth citing at all? */ reply
  3. (diff | hist) m 15:07 Liquid chromatography-mass spectrometry 4,463 ±0 ReceptorRhoda (talk | contribs) add the forced-degradation conditions the claim rests on [rollback]
  4. (diff | hist) 15:04 Zhuhai Kerui Biotechnology 14,711 ±0 DulaglutideDug (talk | contribs) rm the comparison with another supplier; there is no common basis for it [rollback]
  5. (diff | hist) 14:20 Talk:Bacterial endotoxin test 748 +126 EndotoxinEd (talk | contribs) /* Recombinant factor C */ reply
  6. (diff | hist) 13:05 Talk:Syringe dead space 674 +363 VerifyFirstVida (talk | contribs) /* Is the community measurement tally worth citing at all? */ new section
  7. (diff | hist) m 11:44 Retatrutide 7,421 ±0 MazdutideMads (talk | contribs) move a stray full stop inside the reference [rollback]
  8. (diff | hist) 10:45 Talk:Bacterial endotoxin test 537 +157 NewLabNell (talk | contribs) /* Recombinant factor C */ new section
  9. (diff | hist) m 10:42 Bacteriostatic water 4,652 ±0 DefinedTermDov (talk | contribs) convert the conversion list to a table so the three syringe scales align [rollback]
  10. (diff | hist) m b 09:26 Insulin secretion 6,940 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  11. (diff | hist) 08:49 Cost per milligram 4,125 ±0 RepackRadek (talk | contribs) clarify that a discontinued shortage listing changed the compounding position [rollback]
  12. (diff | hist) 08:20 Talk:PeptideMeter 959 +109 SecondarySrc_Seb (talk | contribs) /* Should we import external tallies? */ reply
  13. (diff | hist) m 07:20 List of GLP-1 receptor agonists 3,862 ±0 Chromatokid (talk | contribs) rm the entry that has no article and no planned title [rollback]
  14. (diff | hist) 05:30 Cold-chain freight 4,758 ±0 CrudePeptidePearl (talk | contribs) rm the blanket claim that excursions are harmless [rollback]
  15. (diff | hist) 04:28 Peptide stability table 6,886 ±0 Hedgerow_Hal (talk | contribs) add the source for each stability figure in the table [rollback]
  16. (diff | hist) m 00:34 Test report forgery 5,391 ±0 UnderfillUna (talk | contribs) expand §Forms and their detectability [rollback]

5 April 2026

  1. (diff | hist) m 23:11 MOTS-c 4,670 ±0 MOTSc_Mira (talk | contribs) add reconstitution guidance already agreed on the talk page [rollback]
  2. (diff | hist) m 23:08 Number needed to treat 4,718 ±0 GradientGus (talk | contribs) serial comma per PP:MOS [rollback]
  3. (diff | hist) 21:35 Flourishglobal Peptide Biotech 14,771 ±0 CapitalisationCaz (talk | contribs) add the transit window each regional warehouse serves [rollback]
  4. (diff | hist) 16:42 Trifluoroacetate counterion 5,116 ±0 GMP_Gita (talk | contribs) state the column chemistry and the gradient the figure was obtained on [rollback]
  5. (diff | hist) 14:00 Talk:SELECT trial 748 +115 SafetySignalSid (talk | contribs) /* Discontinuation rate in the summary */ reply
  6. (diff | hist) 12:30 Talk:PeptideMeter 748 +161 NPOV_Nadia (talk | contribs) /* Should we import external tallies? */ reply
  7. (diff | hist) 10:27 Talk:Cold chain 2,003 +231 ScopeSeverin (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply
  8. (diff | hist) 10:25 Talk:SELECT trial 537 +157 BalanceBirdie (talk | contribs) /* Discontinuation rate in the summary */ new section
  9. (diff | hist) 09:50 Talk:PeptideMeter 537 +87 SecondarySrc_Seb (talk | contribs) /* Should we import external tallies? */ new section
  10. (diff | hist) m b 07:59 Active pharmaceutical ingredient 4,569 ±0 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  11. (diff | hist) m 06:32 Oral semaglutide 4,582 ±0 INN_Ingrid (talk | contribs) expand §The absorption mechanism [rollback]
  12. (diff | hist) m 06:11 Custom peptide synthesis 4,773 ±0 ResinRhoswen (talk | contribs) add category for logistics [rollback]

4 April 2026

  1. (diff | hist) 22:26 PolyPeptide Group (Hangzhou) 18,363 ±0 ChainCustodyChad (talk | contribs) correct the other-designations row — those are trading variants, not subsidiaries [rollback]
  2. (diff | hist) m b 16:31 AmbioPharm 16,492 +642 StubSorterBot (talk | contribs) bot: add supplier category [rollback]
  3. (diff | hist) 08:55 Talk:Dual incretin agonist 822 +79 GIP_Genoveva (talk | contribs) /* The GIP agonist-versus-antagonist problem */ reply
  4. (diff | hist) 08:44 Talk:Cold chain 1,792 +368 EndotoxinEd (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply

3 April 2026

  1. (diff | hist) 18:27 Amylin 5,795 ±0 CaptionCzeslaw (talk | contribs) rm a duplicated category [rollback]
  2. (diff | hist) 16:34 Qingdao Sigma Chemical 15,455 ±0 Peptide_Pete (talk | contribs) rm the price; supplier articles carry no price per PP:VN [rollback]
  3. (diff | hist) 14:47 Semaglutide 10,355 ±0 RetatrutideRuben (talk | contribs) fix a dangling clause [rollback]
  4. (diff | hist) 14:15 Talk:Solid-phase peptide synthesis 748 +99 CouplingCillian (talk | contribs) /* Racemisation invisible to mass */ reply
  5. (diff | hist) 13:45 Talk:Dual incretin agonist 611 +217 IncretinIvo (talk | contribs) /* The GIP agonist-versus-antagonist problem */ reply
  6. (diff | hist) 10:40 Talk:Solid-phase peptide synthesis 537 +121 MassSpecMarv (talk | contribs) /* Racemisation invisible to mass */ new section
  7. (diff | hist) m 09:46 Repackaging 4,759 ±0 SeeAlsoSelma (talk | contribs) alphabetise the see-also list [rollback]
  8. (diff | hist) 09:44 Talk:Glucagon-like peptide-1 1,381 +214 Hedgerow_Hal (talk | contribs) /* Readability of the signalling section */ reply
  9. (diff | hist) 09:20 Talk:Dual incretin agonist 400 +210 GIP_Genoveva (talk | contribs) /* The GIP agonist-versus-antagonist problem */ new section
  10. (diff | hist) 09:15 Talk:Cold chain 1,581 +348 ColdChainCleo (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply
  11. (diff | hist) 09:05 Talk:Regulatory status by jurisdiction 822 +97 StateBoardStace (talk | contribs) /* Structure of the jurisdiction material */ reply
  12. (diff | hist) m b 04:17 Insulin syringe 4,944 ±0 StubSorterBot (talk | contribs) bot: add stub category [rollback]

2 April 2026

  1. (diff | hist) 19:06 Talk:Glucagon-like peptide-1 1,170 +267 NewLabNell (talk | contribs) /* Readability of the signalling section */ reply
  2. (diff | hist) 18:48 Aspiration risk under anaesthesia 4,681 ±0 DulaglutideDug (talk | contribs) add the time course: most of these events are early and transient [rollback]
  3. (diff | hist) 15:02 Talk:Cold chain 1,370 +367 NPOV_Nadia (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply
  4. (diff | hist) 14:12 Talk:GLP-1 receptor 611 +171 Chromatokid (talk | contribs) /* Immunohistochemistry caveat */ reply
  5. (diff | hist) 13:20 Talk:USP General Chapter 71 611 +156 EndotoxinEd (talk | contribs) /* Pore size is a convention */ reply
  6. (diff | hist) 13:15 Talk:Regulatory status by jurisdiction 611 +169 ScopeSeverin (talk | contribs) /* Structure of the jurisdiction material */ reply
  7. (diff | hist) 11:38 Talk:Cold chain 1,159 +306 ScopeSeverin (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply
  8. (diff | hist) 10:30 Talk:GLP-1 receptor 400 +254 ReceptorRhoda (talk | contribs) /* Immunohistochemistry caveat */ new section
  9. (diff | hist) 10:00 Talk:Cold chain 948 +516 RfC_Rasmus (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ new section
  10. (diff | hist) 09:45 Talk:USP General Chapter 71 400 +151 NewLabNell (talk | contribs) /* Pore size is a convention */ new section
  11. (diff | hist) 09:40 Talk:Regulatory status by jurisdiction 400 +203 ImportPolicyIggy (talk | contribs) /* Structure of the jurisdiction material */ new section

1 April 2026

  1. (diff | hist) 19:52 Glucagon 7,074 ±0 IcodecIndra (talk | contribs) serial comma per PP:MOS [rollback]
  2. (diff | hist) m b 17:30 Glucagon-like peptide-1 12,294 ±0 CiteBot (talk | contribs) bot: normalise citation format [rollback]
  3. (diff | hist) m 15:14 Underfilling 4,882 ±0 TitrationTheo (talk | contribs) fix a dangling clause [rollback]
  4. (diff | hist) m 13:42 Missed dose 5,277 ±0 NurseNoteNessa (talk | contribs) add the disclaimer that this is not administration guidance [rollback]
  5. (diff | hist) 13:15 Talk:Aspiration risk under anaesthesia 611 +132 HedgeHedda (talk | contribs) /* Caution proportionate to severity, not evidence */ reply
  6. (diff | hist) 10:58 Talk:Multi-dose vial 1,444 +92 BalanceBirdie (talk | contribs) /* Weight of the outbreak section */ reply
  7. (diff | hist) 09:40 Talk:Aspiration risk under anaesthesia 400 +173 AnaesthesiaAoife (talk | contribs) /* Caution proportionate to severity, not evidence */ new section
  8. (diff | hist) 08:50 Tianjin Finder Chemical 14,449 ±0 SecondarySrc_Seb (talk | contribs) move a stray full stop inside the reference [rollback]
  9. (diff | hist) m 08:36 Electrospray ionisation 4,323 ±0 ChromCleanupCass (talk | contribs) rm the vendor name from a methodological sentence [rollback]
  10. (diff | hist) m 01:30 Patent expiry and biosimilars 4,553 ±0 Chromatokid (talk | contribs) add the note that this wiki does not give legal advice [rollback]
  11. (diff | hist) 01:12 Syringe dead space 20,859 ±0 AppendixAlva (talk | contribs) correct the unit conversion — U-100 not U-40 [rollback]

31 March 2026

  1. (diff | hist) m 23:58 VendorInvestigate 5,067 ±0 GroupBuyGalen (talk | contribs) sentence case in headings per PP:MOS [rollback]
  2. (diff | hist) 22:26 Deamidation 5,263 ±0 MassSpecMarv (talk | contribs) correct the flow rate — the source gives it in mL/min [rollback]
  3. (diff | hist) m 20:49 Sigma-Aldrich (Shanghai) Trading 18,641 ±0 BatchNumberBede (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  4. (diff | hist) 20:14 Mass spectrometry 5,612 ±0 PharmDrafts (talk | contribs) expand §Ionisation and mass analysis [rollback]
  5. (diff | hist) 17:54 Retention time 4,104 ±0 PeakShapePol (talk | contribs) split §Principle from §Practical limitations [rollback]
  6. (diff | hist) 15:51 Area percent purity 8,537 ±0 Retention_Time_Rae (talk | contribs) correct the water-content figure — the source reports it on a dry basis [rollback]